Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

In this study (n=847), addition of pembrolizumab to chemotherapy improved progression-free survival (9.7 months vs 5.6 months placebo; HR 0.65, 95% CI 0.49–0.86; p=0.0012) among patients with PD-L1 expression combined positive score of ≥10. Overall survival follow-up is ongoing.

Source:

The Lancet